Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.

CONCLUSION: Eltrombopag not only shows excellent initial response but also has continued efficacy and safety. Patients with megakaryocyte count ≥100/slide and Treg<4.5% achieve increased initial response and more frequent durable response. PMID: 33357172 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research